DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights

Company Performance - DaVita HealthCare is expected to report earnings of $2.47 per share on August 6, 2024, reflecting a year-over-year growth of 18.75% [1] - The consensus estimate for revenue is $3.16 billion, which represents a 5.43% increase from the prior-year quarter [1] - For the entire fiscal year, earnings are projected at $9.62 per share and revenue at $12.74 billion, indicating changes of +13.58% and +4.97% respectively from the previous year [8] Valuation Metrics - DaVita HealthCare currently has a Forward P/E ratio of 14.46, which is below the industry average of 23.51, indicating it is trading at a discount [2] - The company holds a PEG ratio of 1.06, compared to the industry average PEG ratio of 2.07, suggesting a more favorable valuation relative to growth expectations [9] Market Performance - In the latest trading session, DaVita HealthCare closed at $136.47, down 1.93%, underperforming the S&P 500's daily loss of 0.5% [5] - Over the past month, shares have appreciated by 0.4%, underperforming the Medical sector's gain of 0.74% but outperforming the S&P 500's gain of 0.1% [10] Analyst Sentiment - Recent revisions to analyst forecasts for DaVita HealthCare are important as they reflect short-term business trends, with positive revisions seen as a good sign for the company's outlook [3] - DaVita HealthCare currently holds a Zacks Rank of 3 (Hold), with no change in the Zacks Consensus EPS estimate over the past month [11]